CD-Venture
VC Fund
Heidelberg, Germany
CD-Venture is a VC fund in Heidelberg focused on Health Care and Biotechnology. C.D. Ventures works collaboratively with clients to design sustainable change management solutions in Texas.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries CD-Venture invests in
Health CareBiotechnologyPharmaceuticalMedicalInformation Technology
Stages CD-Venture invests in
Series BSeries CSeries ASeedSeries D
Countries CD-Venture invests in
GermanyUnited States
Investment Focus
Industry
- Health Care 4 (36%)
- Biotechnology 4 (36%)
- Pharmaceutical 4 (36%)
- Medical 3 (27%)
- Information Technology 2 (18%)
Stage
- Series B 3 (27%)
- Series C 3 (27%)
- Series A 2 (18%)
- Seed 1 (9%)
- Series D 1 (9%)
Country
- Germany 5 (45%)
- United States 2 (18%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Wellth
|
Our healthcare system assumes we make decisions based on what is best for us. But it’s not that simple. Everyday stressors often cloud our judgement as to what’s best in the long run. For people with chronic conditions, this can make healthy habit formation difficult. Wellth is a venture-backed digital health company that improves adherence inchronic disease populations. Using the science of behavioral economics—combined with an appreciation for human nature—we uncover and address the unique obstacles that prevent people with chronic conditions from improving patient outcomes. Our program goes beyond current efforts to boost adherence with technology, reminders, and coaching solutions using contingency management and loss aversion to create motivation, behavior change and improve population health at scale.In addition to our RCT-proven outcomes, our easy-to-use mobile platform experience has been proven by health plans, providers, and other organizations to empower members with the incentives and support system they need to establish new healthy habits. Key outcomes for members include improved med and care plan adherence, reduction in readmissions, hospitalizations, and ED utilization, improved PDC, and more. Learn more at www.wellthapp.com. | $36M / Series C / Aug 20, 2025 | |
leon nanodrugs
|
leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. | Series D / Aug 06, 2024 | |
|
Wellth
|
Our healthcare system assumes we make decisions based on what is best for us. But it’s not that simple. Everyday stressors often cloud our judgement as to what’s best in the long run. For people with chronic conditions, this can make healthy habit formation difficult. Wellth is a venture-backed digital health company that improves adherence inchronic disease populations. Using the science of behavioral economics—combined with an appreciation for human nature—we uncover and address the unique obstacles that prevent people with chronic conditions from improving patient outcomes. Our program goes beyond current efforts to boost adherence with technology, reminders, and coaching solutions using contingency management and loss aversion to create motivation, behavior change and improve population health at scale.In addition to our RCT-proven outcomes, our easy-to-use mobile platform experience has been proven by health plans, providers, and other organizations to empower members with the incentives and support system they need to establish new healthy habits. Key outcomes for members include improved med and care plan adherence, reduction in readmissions, hospitalizations, and ED utilization, improved PDC, and more. Learn more at www.wellthapp.com. | $20M / Series B / Mar 30, 2023 | |
|
Wellth
|
Our healthcare system assumes we make decisions based on what is best for us. But it’s not that simple. Everyday stressors often cloud our judgement as to what’s best in the long run. For people with chronic conditions, this can make healthy habit formation difficult. Wellth is a venture-backed digital health company that improves adherence inchronic disease populations. Using the science of behavioral economics—combined with an appreciation for human nature—we uncover and address the unique obstacles that prevent people with chronic conditions from improving patient outcomes. Our program goes beyond current efforts to boost adherence with technology, reminders, and coaching solutions using contingency management and loss aversion to create motivation, behavior change and improve population health at scale.In addition to our RCT-proven outcomes, our easy-to-use mobile platform experience has been proven by health plans, providers, and other organizations to empower members with the incentives and support system they need to establish new healthy habits. Key outcomes for members include improved med and care plan adherence, reduction in readmissions, hospitalizations, and ED utilization, improved PDC, and more. Learn more at www.wellthapp.com. | $10M / Series A / May 06, 2020 | |
TriOptoTec
|
TriOptoTec GmbH develops and markets products and services in the area of photodynamic disinfection and decontamination, using its brand „dyphox“. | Series C / Apr 21, 2020 | |
|
leon nanodrugs
|
leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs.leon-nanodrugs offers access to the next generation of nano-formulated drugswith meaningful differentiation and added patient benefits.They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles. | Series B / Apr 16, 2020 | |
Curetis
|
Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases.Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application.However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases. | $15.9M / Series B / Nov 20, 2014 | |
Flex Pharma
|
Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps, cramps and spasms associated. | $40M / Sep 08, 2014 | |
Stocard
|
Stocard’s mission is to become the #1 mobile wallet in the Western world by making the daily shopping experience easy, engaging and rewarding for it's more than 50 million users.By turning shopper’s phones into their wallet, they’ve simplified the way users are rewarded at their favorite stores and are adding an easy way for their users toget access to financial services on the platform.To date several billion transactions at the point of sale have been facilitiated through Stocard. | $850K / Seed / Dec 11, 2012 | |
|
Curetis
|
Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases.Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application.However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases. | $6.5M / Series A / May 17, 2011 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Enterprise Investors
77,348 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
SaaS VC Funds
61,208 investors
Enterprise VC Funds
49,693 investors
Health Care VC Funds
32,370 investors
FAQ
What does CD-Venture invest in?
CD-Venture invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 11 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did CD-Venture last invest?
The most recent investment recorded for CD-Venture closed in Aug 2025. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
